salmeterol xinafoate has been researched along with Cystic Fibrosis in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (25.00) | 18.2507 |
| 2000's | 5 (62.50) | 29.6817 |
| 2010's | 1 (12.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Couriel, J; Evans, HJ; Halfhide, C | 2 |
| Balossier, G; Coraux, C; Delavoie, F; Michel, J; Milliot, M; Molinari, M; Zahm, JM | 1 |
| Bebok, Z; Collawn, JF; Matalon, S | 1 |
| D'Andria, M; Salvatore, D | 1 |
| Colombo, JL; Hordvik, NL; Judy, CG; Sammut, PH | 2 |
| Bargon, J; Buhl, R; Dauletbaev, N; Viel, K; Wiewrodt, R | 1 |
2 review(s) available for salmeterol xinafoate and Cystic Fibrosis
| Article | Year |
|---|---|
WITHDRAWN: Inhaled bronchodilators for cystic fibrosis.
Topics: Adrenergic beta-Agonists; Adult; Albuterol; Bronchial Hyperreactivity; Bronchodilator Agents; Child; Cystic Fibrosis; Humans; Ipratropium; Randomized Controlled Trials as Topic; Salmeterol Xinafoate | 2016 |
Inhaled bronchodilators for cystic fibrosis.
Topics: Adrenergic beta-Agonists; Adult; Albuterol; Bronchial Hyperreactivity; Bronchodilator Agents; Child; Cystic Fibrosis; Humans; Ipratropium; Randomized Controlled Trials as Topic; Salmeterol Xinafoate | 2005 |
4 trial(s) available for salmeterol xinafoate and Cystic Fibrosis
| Article | Year |
|---|---|
Effects of salmeterol on arterial oxyhemoglobin saturations in patients with cystic fibrosis.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Cystic Fibrosis; Female; Humans; Hypoxia; Male; Oxyhemoglobins; Salmeterol Xinafoate | 2002 |
Effectiveness and tolerability of high-dose salmeterol in cystic fibrosis.
Topics: Adolescent; Adult; Albuterol; Anti-Bacterial Agents; Blood Pressure; Bronchodilator Agents; Cross-Over Studies; Cystic Fibrosis; Dose-Response Relationship, Drug; Double-Blind Method; Female; Forced Expiratory Volume; Humans; Male; Middle Aged; Pilot Projects; Pulse; Reference Values; Salmeterol Xinafoate; Spirometry; Time Factors; Vital Capacity | 2002 |
Short-term effects of regular salmeterol treatment on adult cystic fibrosis patients.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Cross-Over Studies; Cystic Fibrosis; Female; Humans; Male; Middle Aged; Peak Expiratory Flow Rate; Prognosis; Prospective Studies; Respiratory Function Tests; Salmeterol Xinafoate; Statistics, Nonparametric; Treatment Outcome | 1997 |
Effects of standard and high doses of salmeterol on lung function of hospitalized patients with cystic fibrosis.
Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Adult; Albuterol; Cross-Over Studies; Cystic Fibrosis; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Forced Expiratory Volume; Genotype; Hospitalization; Humans; Male; Pulmonary Ventilation; Salmeterol Xinafoate; Spirometry; Treatment Outcome | 1999 |
2 other study(ies) available for salmeterol xinafoate and Cystic Fibrosis
| Article | Year |
|---|---|
Salmeterol restores secretory functions in cystic fibrosis airway submucosal gland serous cells.
Topics: Albuterol; Cell Line; Cell Polarity; Chlorides; Colforsin; Cyclic AMP; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Electrophysiological Phenomena; Epithelial Cells; Exocytosis; Humans; Intracellular Space; Ions; Muramidase; Salmeterol Xinafoate; Secretory Vesicles; Serous Membrane; Trachea | 2009 |
Search and rescue: finding ways to correct deltaF508 CFTR.
Topics: Albuterol; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Humans; Ion Channel Gating; Models, Biological; Mutation; Protein Folding; Receptors, Adrenergic, beta-2; Salmeterol Xinafoate | 2009 |